All
FDA’s Abecma Approval a ‘Great Blessing’ for Patients with Multiple Myeloma
April 30th 2021The Food and Drug Administration’s recent approval of Abecma is an extremely significant development for patients with heavily pretreated multiple myeloma, according to an expert from the Dana-Farber Cancer Institute.
Maria Lim, B.S.N., RN, OCN, BMTCN Wins CURE®’s 2021 Extraordinary Healer® Award for Oncology Nursing
April 30th 2021CURE Media Group also recognized Jennifer E. Giovanni, Ph.D., MSN, MPH, RN, as winner of the Finest Hour Award, which highlights the dedication and selflessness exhibited in front-line workers during the COVID-19 pandemic.
Transportation to Cancer Treatments is An Issue for Many Patients
April 29th 2021As transportation to treatments is one of the many important aspects patients with cancer must consider after receiving a diagnosis, there is room for improvement in terms of accessibility and affordability, says an expert from the Patient Access Network Foundation.
Olympic Medalist Uses Mother’s Cancer Journey to Educate and Inspire
April 29th 2021On this episode on the “CURE® Talks Cancer” podcast, we spoke with U.S. beach volleyball Olympic medalist April Ross about how her mother’s experience with metastatic breast cancer gives her the inspiration she needs to pursue her goals and educate others about the disease.
Veterans with Prostate Cancer Are Underassessed And Undertreated For Cardiovascular Risk Factors
April 28th 2021A recent analysis of veterans with prostate cancer showed that they are not being assessed and treated for cardiovascular risk factors at the rate they should be to optimize survival, particularly when being treated with androgen deprivation therapy, which has been associated with increased risk for cardiovascular disease.
Novel Therapy May Address ‘High Unmet Clinical Need’ in Recurrent/Metastatic Cervical Cancer
April 28th 2021Treatment with tisotumab vedotin, a novel antibody-drug conjugate, in women with recurrent or metastatic cervical cancer, led to an objective response rate of 24% with a manageable safety profile.